Immunomodulatory drugs (IMiDs) are a cornerstone in the treatment of multiple myeloma (MM), but specific markers to predict outcome are still missing. Recent work pointed to a prognostic role 
| I N T R O D U C T I O N
Clinical progress in the treatment of multiple myeloma (MM) is chiefly based on the introduction of immunomodulatory drugs (IMiDs), proteasome inhibitors, and monoclonal antibodies, but valid biomarkers for the stratification of patients to individualized treatment approaches are still lacking. In this context, the identification of cereblon as a central mediator of IMiD-mediated drug effects represents a major breakthrough in the search for personalized treatment options. 1, 2 Cereblon is required for the anti-MM activity of IMiDs and, accordingly, we and others demonstrated that high cereblon mRNA or protein levels predicted response and/or superior survival in myeloma patients treated with IMiDs. [3] [4] [5] [6] However, the complexity of cereblon mediated drug mechanisms, that is, the presence of several cereblon splice variants and the lack of standardized reagents, 7 currently limits the use of cereblon expression as a predictive marker in clinical routine.
More recent studies identified IKAROS (IKZF1) and AIOLOS (IKZF3)
as targets for lenalidomide-cereblon mediated ubiquitination. 8, 9 Both, Contrary results were obtained in T cells, where lenalidomide mediated reduction of IKAROS and AIOLOS was associated with IL-2 production and T cell activation. 9, 12 In addition, more recent results revealed several other IMiD-cereblon associated targets such as KPN2A, argonaute 2,
MCT-1 and CD147. [13] [14] [15] This suggests an important role for these proteins in the direct as well as the indirect anti-MM activity of IMiDs.
A recent study also reported that pomalidomide mediated activation of CD8 1 T cells was associated with clinical response but not IKAROS or AIOLOS baseline levels in MM cells. 16 
| Analysis of gene expression profiling (GEP) data
Analysis of publically available GEP-data was performed using the , and MM-BM in vitro generated osteoclasts (n 5 7). 19 Raw CEL files were downloaded into R, rma normalized using the "affy"
package from Bioconductor and subsequently used for statistical analyses.
| Statistical analysis
Statistical analysis of GEP data was performed using R's multiple U tests were performed using Prism 6 (GraphPad Software, La Jolla, CA). Optimal cut offs for survival analysis were determined using CutOff Finder. 20 Cox regression analysis was performed using SPSS 17.0. P values .05 were considered to be statistically significant. 
| R E S U LTS

| Correlations between IMiD target genes and clinical parameters
We observed a significant correlation of CRBN expression levels with MCT-1 (R 5 0.34, P 5 .03) and a trend for CD147 (R 5 0.27, P 5 .08).
The strong interaction of the analysed genes was further depicted by a significant association of MCT-1 with IRF4 (R 5 0.49, P 5 .001), CD147
(R 5 0.71, P < .001), IKZF1 (R 5 0.31, P 5 .04), and IKZF3 (R 5 20.31, P 5 .04) as well as CD147 with IRF4 (R 5 0.39, P 5 .009), and IKZF1
(R 5 0.68, P < .001).
Regarding correlations with clinical parameters we found a significant association of CD147 (R 5 0.35, P 5 .046) and MCT-1 (R 5 0.63, Figure S1 ). Figure 2D ). In sum, these data demonstrated that the plasma cell marker IRF4 was consistently upregulated in MM cells, while IKZF1
was enriched in environmental cells compared with CD138 1 cells.
Based on these results we selected IKAROS as potential marker of IMiD activity in BM stromal cells.
| Evaluation of IKAROS protein levels in distinct BM cell subsets
IKAROS protein levels in distinct cell compartments of the BM were analysed by flow cytometry. To check the robustness of our retrospective Figure 3A) . Gene expression levels of CRBN, IKZF1, IRF4, CD147, and MCT-1 were significantly higher in patients with response to therapy ( PR, n 5 32) in comparison with nonresponders (stable or progressive disease, n 5 12). No association between response and whole BM mRNA expression was found for IKZF3. Graphs display median gene expression levels with interquartile range relative to expression in whole BM mononuclear cells of independent MM patients (n 5 7). CR, complete response; VGPR, very good partial response; PR, partial response; SD, stable disease; PD, progressive disease. Gene expression is displayed relative to BM CD138 1 MM cells of 13 independent myeloma patients. B: Gene expression of IMiD target genes in distinct BM cell subsets of myeloma patients was analysed using publically available GEP data (E-TABM-937). Asterisks indicate statistically significant differential expression compared with MM cells (*P < .05, **P < .01, ***P < .001). MM cells, CD138 
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We then employed this flow cytometry based assay to measure Figure 3B ). 18.0 months, P 5 .01; Figure 5 ).
| IKAROS protein expression in environmental cell populations is associated with outcome
| IKAROS protein levels post treatment with lenalidomide-dexamethasone
We finally analysed IKAROS levels after lenalidomide-dexamethasone therapy in serial samples of four patients. IKAROS 1 BM MNCs decreased in three patients and slightly increased in one patient. 
| DISCUSSION
We previously demonstrated the predictive value of CRBN expression in whole BM samples, suggesting that the BM stromal compartment might play a central role in IMiD mediated antimyeloma effects. 4 Normalization of whole BM GEP was recently also linked to superior prognosis and therefore underlined the applicability and importance of stromal gene expression for prognostication. 21 In this study, we were able to confirm the association between to a potential T cell activation post therapy. 24 However, a possible association between IKAROS 1 immune cells in MM and their activation status has to be clarified in future studies.
In MM cells, GEP determined IKZF1 mRNA expression was linked to response and outcome in pomalidomide treated patients. 13 Interestingly, IKZF1 expression levels were also reported to be associated with complete response in patients treated with bortezomib, thalidomide and dexamethasone. 25 In contrast, we did not find an association between baseline IKAROS protein levels in MM cells and OS. This is in line with a prior study reporting no impact of IKAROS and AIOLOS baseline levels in MM cells (determined by immunohistochemistry) and response or survival. 16 Although we observed superior PFS in patients with high MFI values in MM cells and this might translate to OS in larger patient cohorts, possibly the kinetics of IKAROS (or AIOLOS) degradation in MM cells might be more informative than baseline levels. 26 The here described value of IKAROS as potential prognostic marker for IMiD based therapies is, however, clearly limited by the ret- 
C O NF LI C T S OF I N T ER EST
The authors declare that they have no relevant conflicts of interest. 
